

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(U.S. dollars in thousands, except for share and per-share amounts)

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2015 Unaudited</b>	<b>2014 Unaudited</b>	<b>2015 Unaudited</b>	<b>2014 Unaudited</b>
Revenues	229	1,718	964	5,815
Cost of revenues	201	741	597	2,357
<b>Gross profit</b>	<b>28</b>	<b>977</b>	<b>367</b>	<b>3,458</b>
<b>Operating expenses</b>				
Research and development expenses, net	5,334	3,910	15,444	10,226
Marketing and business development expenses	267	156	745	438
General and administrative expenses	1,341	1,504	4,369	4,016
<b>Total operating expenses</b>	<b>6,942</b>	<b>5,570</b>	<b>20,558</b>	<b>14,680</b>
<b>Operating loss</b>	<b>(6,914)</b>	<b>(4,593)</b>	<b>(20,191)</b>	<b>(11,222)</b>
Financial income (loss), net	172	(802)	500	1,670
<b>Net loss before taxes</b>	<b>(6,742)</b>	<b>(5,395)</b>	<b>(19,691)</b>	<b>(9,552)</b>
Taxes on income	-	-	-	(60)
<b>Net loss</b>	<b>(6,742)</b>	<b>(5,395)</b>	<b>(19,691)</b>	<b>(9,612)</b>
Basic and diluted net loss per ordinary share	(0.13)	(0.11)	(0.39)	(0.20)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	50,469,567	49,089,165	50,406,864	47,021,655

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS DATA**  
(U.S. dollars, in thousands)

	September 30, 2015 <u>(Unaudited)</u>	December 31, 2014 <u>(Audited)</u>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash, cash equivalents, short-term bank deposits and restricted cash	74,271	73,328
Investment in Evogene	933	1,054
Other accounts receivable and prepaid expenses	1,892	716
<b>Total current assets</b>	<b>77,096</b>	<b>75,098</b>
<b>Non-current assets</b>		
Long-term bank deposits	15,008	35,026
Non-current prepaid expenses	106	108
Severance pay fund	2,128	2,024
Property and equipment, net	2,738	2,730
<b>Total non-current assets</b>	<b>19,980</b>	<b>39,888</b>
<b>Total assets</b>	<b>97,076</b>	<b>114,986</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Other account payables, accrued expenses and trade payables	4,214	4,379
Deferred revenues	824	1,789
Research and development funding arrangement	105	421
<b>Total current liabilities</b>	<b>5,143</b>	<b>6,589</b>
<b>Non-current liabilities</b>		
Accrued severance pay	2,524	2,281
<b>Total non-current liabilities</b>	<b>2,524</b>	<b>2,281</b>
<b>Total shareholders' equity</b>	<b>89,409</b>	<b>106,116</b>
<b>Total liabilities and shareholders' equity</b>	<b>97,076</b>	<b>114,986</b>